Table 5 The second ATC classification level of cardiovascular system drugs used by patients with CVDs
Drug class | Total n = 961 (100%) | Men (Total n = 404) n (%; 95% CI) | Women (Total n = 557) n (%; 95% CI) | 60 years and older (Total n = 441) n (%; 95% CI) |
|---|---|---|---|---|
C09 | 362 (37.6) | 143 (35.4; 29.8–41.7) | 219 (39.3; 34.2–44.8) | 189 (42.8; 36.9–49.4) |
C07 | 344 (35.8) | 121 (29.9; 24.8–35.7) | 223 (40.0; 34.9–45.6) | 165 (37.4; 31.9–43.5) |
C01 | 291 (30.2) | 128 (31.6; 26.4–37.6) | 163 (29.2; 24.9–34.1) | 173 (39.2; 33.6–45.5) |
C10 | 266 (27.6) | 118 (29.2; 24.1–34.9) | 148 (26.5; 22.4–31.2) | 133 (30.1; 25.2–35.7) |
C08 | 150 (15.6) | 39 (9.6; 6.8–13.2) | 111 (19.9; 16.3–24.0) | 99 (22.4; 18.2–27.3) |
C03 | 80 (8.3) | 39 (9.6; 6.8–13.2) | 41 (7.3; 5.2–9.9) | 45 (10.2; 7.4–13.6) |
C05 | 16 (1.6) | 7 (1.7; 0.7–3.5) | 9 (1.6; 0.7; 3.0) | 6 (1.3; 0.5–2.9) |
C02 | 7 (0.7) | 4 (0.9; 0.2–2.5) | 3 (0.5; 0.1–1.5) | 5 (1.1; 0.3–2.6) |